We are live on ! Find out more
IMUX icon

Immunic

61 hedge funds and large institutions have $92.4M invested in Immunic in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

49% more capital invested

Capital invested by funds: $62.1M → $92.4M (+$30.3M)

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

11% more funds holding

Funds holding: 5561 (+6)

0.02% more ownership

Funds ownership: 6.2%6.22% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

83% less call options, than puts

Call options by funds: $118K | Put options by funds: $698K

Holders
61
Holders Change
+6
Holders Change %
+10.91%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
12
Increased
17
Reduced
14
Closed
5
Calls
$118K
Puts
$698K
Net Calls
-$580K
Net Calls Change
-$221K

IMUX Hedge Fund Activity: Q3 2024 in Review

61 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2024, worth a combined $92.4M — up 49% from $62.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IMUX positions and 5 closed out — a net gain of 7 holders — while 17 added to existing stakes and 14 trimmed.

The largest buyer was Focus Partners Wealth, opening a new position worth an estimated $3.05M. The largest seller was Janus Henderson Group, cutting an estimated $2.81M.

  • 61 institutional investors held Immunic (IMUX) as of Q3 2024, up from 55 in Q2 2024.
  • Funds reported $92.4M of Immunic stock for Q3 2024, up 49% quarter-over-quarter.
  • 12 funds opened new Immunic positions in Q3 2024 and 5 closed out, a net change of +7 holders.
  • The largest Immunic buyer in Q3 2024 was Focus Partners Wealth, an estimated $3.05M added.
  • The largest Immunic seller in Q3 2024 was Janus Henderson Group, an estimated $2.81M sold.

Based on aggregated 13F filings for Q3 2024.